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Tegretol in the Treatment of Diabetic Neuropathy
T. D. WILTON
SUMMARY
Patients suffering from peripheral neuropathy caused by
diabetes mellitus were admitted to a double-blind trial
comparing the efficacy of Tegretol (carbamazepine) and
placebo. Objective and subjective parameters were
measured to assess the effect of the treatment.
Significant relief of pain was obtained, often within
a few days, on a dosage of 200 mg Tegretol t.d.s. No
interference with diabetic control was observed.
S. AII'. Med. J., 48, 869 (1974)
Pathologically, diabetic neuropathy IS a segmental de-
generation of the peripheral nerve. In some cases it is
related to vessel narrowing or occlusion, while in other
instances no apparent cause can be demonstrated. The
resulting functional loss involves both motor and sensory
fibres of the peripheral nerve, and usually the lower limb
exhibits more severe disease than the upper.
Clinically, the condition is heralded by the onset of
paraesthesia of limbs, fingers and toes; burning sensa-
tion of hands and feet; cramps and pains in the legs and
muscles. Very often there is a characteristic diurnal varia-
tion, being worse at night and causing sleeplessness. In
some instances, the disease is so severe that patients
cannot endure blankets on their feet, even in midwinter.
It is a disease of great frequency-perhaps greater than
is generally appreciated. The Natalspruit Hospital Diabetic
Clinic has just completed a survey of the incidence of
diabetic neuropathy, and at this stage the estimate is in the
vicinity of 30°6 of cases (results to be published).
PATIENTS AND METHODS
The Trial
Forty patients were selected for a double-blind, within-
patient cross-over trial comparing Tegretol and a placebo.
Most of these patients had previously been treated for
diabetic neuropathy and the usual treatments employed
had met with little or no success.
The dosage used was Tegretol 200 mg f.d.s. and an
identical placebo dosage. The trial was over a 4-week
period. At day 0, following a wash-out period of 2 weeks,
the patients were admitted, assessed and put onto either
Tegretol or placebo, according to a prerandomised
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balanced sequence. At day 7 patients were crossed over
from Tegretol to placebo or vice versa.
The patients were asked to evaluate their own symp-
toms using an analogue scale, and independent assess-
ments were made by the investigator. At the end of the
treatment period a preference statement was made in-
dependently by the patients and the investigator. Obser-
vations were carried out on days 0, 3, 7, 10 and 14, with
full neurological examinations on each occasion.
The Patients
Forty patients were studied and with 1 exception, a
Coloured woman, all were Black. All patients at time of
admission were stabilised in terms of their respective
diabetic treatments. All the patients completed the trial
and the following information is pertinent.
The mean age of patients participating in the trial
was 56,4 years (range 28 - 70 years). The sex ratio was
identical for both groups, 75% (30) of the sample being
female. The two treatment subsamples were homogeneous
with respect to height and mass.
An arbitrary period of 3 months was a qualifying con-
dition in terms of neuropathic symptomatology. Seventeen
of the patients had symptoms which were present for
one-and-a-half years or more, and in 8 patients for longer
than 2 years. Thirty patients complained of intermittent
symptoms and 10 suffered constant symptomatology. This
percentage is identical for both groups. The most constant
complaint was a burning pain of the feet and hands.
None of the patients appeared malnourished. None had
an alcoholic history and in no instance was alcoholism
suspected. With one exception, the patients were con-
sidered reliable witnesses. Two patients had hypertension.
Three patients were insulin-dependent diabetics. In all
cases environment was not considered to be a contributory
factor in the aetiology of the neuropathy.
Parameters Measured
The parameters measured were both objective and
subjective.
Subjective parameters included pain; numbness; agita-
tion; ability to sleep; depression and anxiety.
Objective parameters included assessment of pain appre-
ciation-pinprick; assessment of light touch; assessment of
thermal appreciation; assessment of vibration sense in
upper and lower limbs; assessment of position sense; re-
flexes; trophic changes; shininess of the skin; ulcers; ability
to walk; hyperhidrosis; blood pressure; urine analysis;
and fasting blood sugars.
~,
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RESULTS
Relief of Pain
Pain was measured by the patients on a lO-cm analogue
scale. The means and standard errors are given in Table 1.
Probabilities are given in brackets whenever the difference
is statistically significant (tested by means of Student's
t-test).
Numbness
day 3. The two factors discussed above could indicate
either a high placebo response or a disease fluctuation.
From day 3 to day 7, a further fall in the pain score
was observed, and although Tegretol tended to decrease
the pain score at a faster rate than placebo, this difference
was not statistically significant.
From day 7 to day 10 (when crossover took place) the
pain scores of placebo-treated patients increased, whereas
the scores of the Tegretol patients decreased significantly
(P<O,OI).
On days 10 and 14 differences between the treatments
were significant (P<O,05) in favour of Tegretol.
The results of this detailed analysis indicate that Tegretol
is effective in controlling pain in diabetic neuropathy.
Pain was measured by the observer on a 4-point scale
where 0 = absent, I = mild, 2 = moderate and 3 = severe.
The results are tabulated and analysed by the Kruskal-
Wallis H-test. No significant difference was found between
the two subsamples on day O. On days 3 and 7 a tendency
towards significance in favour of Tegretol was observed
(H = 2,88 and 3,09 respectively, P<O,lO). On days 10
and 14 a statistically significant difference (H = 4,39,























Fig. 1. Drug profile-pain.
Inspection of Table I and the drug profile shown in
Fig. 1 indicates a number of important features:
The decrease in score for day 0 to day 3 is statistically
significant (P<O,Ol) for both Tegretol and placebo. No
difference was found between the treatment on day 0 or
Numbness significantly (P<0,05) decreased from day 0
to day 3 for the Tegretol-treated patients (Table 11).
Numbness was also measured on a 4-point scale (0 =
absent, 1 = mild, 2 = moderate and 3 = severe) by the
observer at all 5 assessments. Three patients in the Tegretolf
placebo treatment subsample and 1 in the placebo/Tegretol
subsample were dropped from the analysis, since they
had scores of '0' throughout the treatment period.
TABLE I. PAIN (10-CM ANALOGUE SCALE)






(P<O,OOI) 2,57 :±: 0,76
6,69 -+- 0,75 lI( ~ 2,54 -+- 0,75 1,54 -+- 0,56 !(P<O,05)
(P<O,OI) (P<O,OI)
6,74:±: 0,75 0( ~ 3,46 -+- 0,62 2,48 -+- 0,60 0( ~ 0,35 -+- 0,24
Pretreatment Placebo
TABLE 11. NUMBNESS (lO-CM ANALOGUE SCALE)
Pretreatment Day 3 Day 7 Day 10 Day 14
Tegretol Placebo
(P<O,05)
4,62 -+- 0,88 0( ~ 1,96 -+- 0,66 2,18 -+- 0,78 .
5,92 -+- 0,76 3,93 -+- 6,74 2,01 -+- 0,63
Pretreatment Placebo
1,84 -+- 0,66 1,21 -+- 0,65
O,74:±: 0,54 0,17 :±: 0,16
Tegretol
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Fig. 2. Drug profile-numbness.
Fig. 3. Drug profile-ability to sleep.
The results of the Kruskal-Wallis H-test on this data
showed that there was no significant difference between
the two treatment subsamples on day 0, or between the
treatments on days 3, 7, 10 and 14. With time the numb-
ness improved to a greater extent with Tegretol treatment
than with placebo.
was scored either as 'week 1', 'week 2' or 'no difference'.
Twenty-four patients preferred the active drug Tegretol, 14
preferred placebo and 2 were indifferent.
Investigator's Preference Statement
Ability to Sleep
The patients measured their ability to sleep on a IO-cm
analogue scale. The means and standard errors are given
in Table Ill. The differences were tested by means of the
Student's t-test and, where significant, the probabilities
are given in brackets. One patient with a score of '0'
throughout the period was dropped from the analysis.
Both Tegretol and placebo significantly (P<O,OI) de-
creased the score from day 0 to day 3. On days 0, 3, 7
and 10 there is no significant difference between the two
treatment subsamples. On day 14 the differences between
the two treatments just failed (P<O,I) to reach significance
in favour of Tegretol (Table III and Fig. 3).
Twenty-eight patients improved on the active drug
Tegretol, 9 patients improved on placebo, and 2 were
indifferent. One patient was considered unreliable' and
omitted from the analysis.
The other parameters showed no significant difference.
While it is not possible to include a detailed breakdown of
all other parameters which were measured, this information
is available. In most instances no improvement was anti-
cipated in terms of areflexia, diminished sensation, di-
minished thermal appreciation, etc.
Side-Effects
Patient's Preference Statement
At the end of the trial period the patient was asked
which treatment was preferred. This preference statement
Twenty-five of the 40 patients on Tegretol reported side-
effects, and only 2 on the placebo. Side-effects were in
most instances mild, transient, and of 2 - 3 days' duration.
In view of the dosage regimen side-effects were not
wholly unexpected and did not interfere with treatment.
TABLE Ill. ABILITY TO SLEEP (10-CM ANALOGUE SCALE)
(P<O,01)
4,98 ::±: 0,82 1,22 ± 0,46 0,91 ::±: 0,59
(P<O,01)





Pretreatment Day 3 Day 7
Tegretol
Day 14 Day 21
Placebo
2,44 -+- 0,86 1,13 ± 0,62
(P<O,10)
0,94 -+- 0,47 0,02 -+- 0,00
Tegretol
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• Some patients reported more than one symptom or side-effect.
TABLE IV. SIDE-EFFECTS
DISCUSSION
Forty patients entered this within-patient trial to compare
the efficacy and tolerability of Tegretol against placebo in
the treatment of symptoms due to peripheral neuropathy
caused by diabetes mellitus. Pretreatment homogeneity
indicated the subsample Tegretol as the first drug and
placebo as the second drug, and vice versa, to be com-
pletely homogeneous with respect to age, sex, race, mass,
height, duration of illness, nature of symptoms, spon-
taneous daily fluctuation, previous therapy and concomitant
medication.
Tegretol significantly improved pain (both patient and
observer assessment) compared with placebo. A carry-over
effect appears to be present in a number of cases. No
serious side-effects were encountered in this trial, and
there was no interference with diabetic control.
The complete efficacy of the double-blind system can
be questioned, since the frequency of secondary effects
may serve as an identifying clue to both the patient and
the treating physician.
The results achieved are clinically remarkable if one
considers the severity, chronicity, resistance to therapy
and duration of the disease process.
It is the experience of this clinic that the incidence of
diabetic neuropathy far outstrips that of neurosis, and
that in the past many of us have glossed over the patients'
symptomatology because of the difficulty in offering an
effective therapy. Tegretol is a useful tool in the treatment
of diabetic neuropathy.
Rull, 1. A. (1969): Diabetologia 5, 215.
Wilton, T. D. (1972): S. Afr. Med. J., 46, 1757.
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Vomiting (1 day each) 4
Diarrhoea 1
Paraesthesia left side
of face (2 days)
Anorexia
